Thermo to sell Athena Diagnostics and Lancaster Laboratories
Thermo Fisher Scientific has announced that it will be selling its Athena Diagnostics and Lancaster Laboratories businesses for a total of $940 million.
Thermo Fisher Scientific has announced that it will be selling its Athena Diagnostics and Lancaster Laboratories businesses for a total of $940 million.
Lancaster Laboratories will be sold to Brussels-based laboratory services provider, Eurofins Scientific. Lancaster Laboratories is a contract-testing laboratory that provides comprehensive analytical services for pharmaceutical, biopharmaceutical and environmental sciences customers, with operations in the US and Ireland.
The company will also be selling Athena Diagnostics to Quest Diagnostics. Athena Diagnostics, based in Worcester, Massachusetts, USA, is a reference laboratory that provides comprehensive diagnostic testing for neurological and other diseases, with an emphasis on gene-based tests.
"Athena and Lancaster have performed very well within our company and we believe that these strategic buyers will offer them even greater opportunities for growth in the long term," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. "The transactions position both businesses in companies that are closely aligned with the unique contract laboratory services they provide and, at the same, will generate significant proceeds that we can redeploy to create shareholder value."
Thermo Fisher expects to close these transactions in the second quarter of 2011, subject to customary closing conditions and applicable regulatory approvals.
For more information visit www.thermo.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
